iPAX‑2 Trial of TLX101 in First‑Line Glioblastoma Hits Full Enrollment and Dosing Confirmation

In a development that’s turning heads across the neuro‑oncology community, the iPAX‑2 study – a multicenter Phase II trial evaluating TLX101 (also known as TX) as a first‑line therapy for glioblastoma – announced that it has now completed enrolment. The trial, which began recruiting patients in early 2022, managed to enrol the planned 120 participants across 15 sites in just under two years, a pace the sponsor calls "remarkably swift" given the aggressive nature of the disease.

Beyond the enrolment milestone, the study also confirmed the recommended Phase II dose (RP2D) of TLX101. After a carefully monitored dose‑escalation run‑in, investigators found that 200 mg administered intravenously once weekly struck the right balance between tolerability and pharmacologic activity. No unexpected safety signals emerged, and the most common side‑effects – mild fatigue, transient nausea, and low‑grade liver enzyme elevations – aligned with the drug’s known profile.

"We’re thrilled to have hit both key objectives on schedule," said Dr. Maya L. Cheng, Chief Medical Officer at iPAX Therapeutics. "Completing enrolment gives us a solid foundation to focus on the efficacy data, which we expect to present at the upcoming Society for Neuro‑Oncology meeting. The dosing confirmation reassures us that TLX101 can be administered safely alongside the current standard of care, temozolomide and radiation."

TLX101 is a novel, highly selective inhibitor of the tumor‑associated enzyme TXK, designed to disrupt glioblastoma cell proliferation while sparing healthy brain tissue. Pre‑clinical models showed promising tumor shrinkage, and early Phase I data hinted at improved progression‑free survival compared with historical controls.

With enrolment now closed, the iPAX‑2 study will move into the efficacy assessment phase. Researchers will track overall survival, progression‑free survival, and quality‑of‑life metrics over a 24‑month follow‑up period. An interim analysis is slated for Q3 2026, and the final data package is expected by early 2027.

Industry analysts see TLX101 as a potential game‑changer, especially for patients whose tumors carry the TXK‑amplified signature – a subgroup that currently has limited therapeutic options. If the upcoming efficacy data hold up, the drug could accelerate toward a pivotal Phase III trial, possibly reshaping the first‑line treatment landscape for glioblastoma.

For now, the glioblastoma community watches closely, hopeful that TLX101 will add another weapon to the fight against one of the toughest brain cancers.